What is B. Riley’s Forecast for ATNM FY2025 Earnings?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Equities research analysts at B. Riley lowered their FY2025 earnings estimates for shares of Actinium Pharmaceuticals in a report issued on Tuesday, April 1st. B. Riley analyst Y. Zhi now anticipates that the company will earn ($0.95) per share for the year, down from their previous estimate of $0.16. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share.

A number of other equities research analysts have also issued reports on the stock. StockNews.com raised shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

Actinium Pharmaceuticals Trading Up 2.0 %

Shares of ATNM opened at $1.52 on Thursday. The business’s 50 day moving average is $1.27 and its 200 day moving average is $1.44. Actinium Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $10.24. The company has a market capitalization of $47.42 million, a PE ratio of -1.09 and a beta of 0.10.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Vontobel Holding Ltd. purchased a new position in shares of Actinium Pharmaceuticals in the 4th quarter worth $32,000. Barclays PLC lifted its holdings in shares of Actinium Pharmaceuticals by 323.0% in the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after acquiring an additional 32,784 shares during the last quarter. Sei Investments Co. purchased a new position in Actinium Pharmaceuticals in the fourth quarter worth about $62,000. Wellington Management Group LLP bought a new stake in Actinium Pharmaceuticals during the third quarter worth approximately $112,000. Finally, Bank of America Corp DE raised its position in Actinium Pharmaceuticals by 76.6% during the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after purchasing an additional 34,176 shares during the period. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).